Edition:
United States

Karolinska Development AB (KDEV.ST)

KDEV.ST on Stockholm Stock Exchange

6.40SEK
2 Dec 2016
Change (% chg)

-- (--)
Prev Close
6.40kr
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
21,600
52-wk High
10.00kr
52-wk Low
5.25kr

KDEV.ST

Chart for KDEV.ST

About

Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, women’s health, cardiovascular and hematology, medical... (more)

Overall

Beta: 0.71
Market Cap(Mil.): kr322.16
Shares Outstanding(Mil.): 51.96
Dividend: --
Yield (%): --

Financials

  KDEV.ST Industry Sector
P/E (TTM): -- 32.25 29.87
EPS (TTM): -6.11 -- --
ROI: -55.15 13.46 14.95
ROE: -139.03 17.16 16.29

BRIEF-Karolinska Development Q3 operating loss narrows to SEK 7.0 million

* Q3 net sales 0.4 million Swedish crowns ($43,451) versus 0.3 million crowns year ago

Nov 23 2016

BRIEF-Karolinska Development's Umecrine Cognition raises SEK 45 mln to advance GR3027

* Umecrine Cognition raises 45 million Swedish crowns ($4.9 million) to advance GR3027, a novel drug candidate for hepatic encephalopathy

Nov 22 2016

BRIEF-Karolinska Development: Modus Therapeutics granted US patents for sickle cell disease drug candidate sevuparin

* Karolinska Development company Modus Therapeutics granted U.S. patents for sickle cell disease drug candidate sevuparin

Nov 07 2016

BRIEF-Karolinska Development: positive phase 1 data with GR3027 in hepatic encephalopathy

* Karolinska Development company Umecrine Cognition announces positive phase 1 data with GR3027 in hepatic encephalopathy

Nov 03 2016

BRIEF-Karolinska Development: Aprea Therapeutics updates clinical data of APR-246

* Portfolio company Aprea Therapeutics updates clinical data from phase IB trial of APR-246 in ovarian cancer.

Oct 10 2016

BRIEF-Karolinska Development's Dilafor raises SEK 51 million for study

* Karolinska Development portfolio company Dilafor AB raises 51 million Swedish crowns ($6 million) to facilitate phase IIb clinical study with tafoxiparin

Sep 27 2016

BRIEF-Karolinska Development: collaboration with AbbVie for Parkinson's Disease Research

* Its portfolio company BioArctic enters into collaboration with AbbVie for Parkinson's Disease Research

Sep 20 2016

BRIEF-Karolinska Development: Preliminary data from retrospective study on OSSDSIGN Cranial

* Preliminary data from retrospective study indicates that OSSDSIGN Cranial may provide better, more permanent solution for cranioplasty, even in complex patient population

Sep 05 2016

BRIEF-Karolinska Development Q2 net sales fall to SEK 0.6 mln

* Net sales amounted to 0.6 million Swedish crowns ($70,000) in Q2 (1.1 million crowns in Q2 2015)

Aug 31 2016

BRIEF-Karolinska Development divests holding in Clanotech to Rosetta Capital

* Says KDev Investments, investment fund jointly owned by Karolinska Development and Rosetta Capital, will transfer all its shares in Clanotech to Rosetta Capital

Jul 05 2016

Earnings vs. Estimates